Economics and financing of vaccines for diarrheal diseases

Human Vaccines and Immunotherapeutics

Volumn 10, Issue 6, 2014, Pages 1568-1581

  Bartsch, Sarah M ^a,b   Lee, Bruce Y ^a  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b University of Pittsburgh   (United States)

Author keywords

Burden; Cost effectiveness; Diarrheal diseases; Economics; Gastroenteritis; Vaccines

Indexed keywords

VACCINE;

DIARRHEA; DRUG DEVELOPMENT; ECONOMICS; FINANCIAL MANAGEMENT; HUMAN; IMMUNOLOGY; ISOLATION AND PURIFICATION; PROCEDURES;

CAPITAL FINANCING; DIARRHEA; DRUG DISCOVERY; HUMANS; VACCINES;

EID: 84905866908     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.28885     Document Type: Review

References (95)

1. Murray CJ, Vos T, Lozano R, Naghavi M, Flaxman AD, Michaud C, Ezzati M, Shibuya K, Salomon JA, Abdalla S, et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380:2197-223; PMID:23245608; http://dx.doi.org/10.1016/S0140-6736(12)61689-4
2. Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, Abraham J, Adair T, Aggarwal R, Ahn SY, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380:2095-128; PMID:23245604; http://dx.doi.org/10.1016/S0140-6736(12)61728-0
3. Liu L, Johnson HL, Cousens S, Perin J, Scott S, Lawn JE, Rudan I, Campbell H, Cibulskis R, Li M, et al.; Child Health Epidemiology Reference Group of WHO and UNICEF. Global, regional, and national causes of child mortality: an updated systematic analysis for 2010 with time trends since 2000. Lancet 2012; 379:2151-61; PMID:22579125; http://dx.doi.org/10.1016/S0140-6736(12)60560-1
4. Fischer Walker CL, Sack D, Black RE. Etiology of diarrhea in older children, adolescents and adults: a systematic review. PLoS Negl Trop Dis 2010; 4:e768; PMID:20689809; http://dx.doi.org/10.1371/journal.pntd.0000768
5. Clemens J. Evaluation of vaccines against enteric infections: a clinical and public health research agenda for developing countries. Philos Trans R Soc Lond B Biol Sci 2011; 366:2799-805; PMID:21893543; http://dx.doi.org/10.1098/ rstb.2011.0033
6. Gulland A. Simple measures could prevent more than two million child deaths from pneumonia and diarrhoea. BMJ 2012; 344:e4025; PMID:22685178; http://dx.doi.org/10.1136/bmj.e4025
7. Lee BY, Burke DS. Constructing target product profiles (TPPs) to help vaccines overcome postapproval obstacles. Vaccine 2010; 28:2806-9; PMID:19782109; http://dx.doi.org/10.1016/j.vaccine.2009.09.047
8. Glass RI, Parashar UD, Estes MK. Norovirus gastroenteritis. N Engl J Med 2009; 361:1776-85; PMID:19864676; http://dx.doi.org/10.1056/NEJMra0804575
9. Patel MM, Hall AJ, Vinjé J, Parashar UD. Noroviruses: a comprehensive review. J Clin Virol 2009; 44:1-8; PMID:19084472; http://dx.doi.org/10.1016/j.jcv.2008.10.009
10. Scallan E, Hoekstra RM, Angulo FJ, Tauxe RV, Widdowson MA, Roy SL, Jones JL, Griffin PM. Foodborne illness acquired in the United States-major pathogens. Emerg Infect Dis 2011; 17:7-15; PMID:21192848; http://dx.doi.org/10.3201/ eid1701.P11101
11. Thomas MK, Murray R, Flockhart L, Pintar K, Pollari F, Fazil A, Nesbitt A, Marshall B. Estimates of the burden of foodborne illness in Canada for 30 specified pathogens and unspecified agents, circa 2006. Foodborne Pathog Dis 2013; 10:639-48; PMID:23659355; http://dx.doi.org/10.1089/fpd.2012.1389
12. Ruzante JM, Majowicz SE, Fazil A, Davidson VJ. Hospitalization and deaths for select enteric illnesses and associated sequelae in Canada, 2001-2004. Epidemiol Infect 2011; 139:937-45; PMID:20731884; http://dx.doi.org/10.1017/ S0950268810001883
13. Tam CC, Rodrigues LC, Viviani L, Dodds JP, Evans MR, Hunter PR, Gray JJ, Letley LH, Rait G, Tompkins DS, et al.; IID2 Study Executive Committee. Longitudinal study of infectious intestinal disease in the UK (IID2 study): incidence in the community and presenting to general practice. Gut 2012; 61:69-77; PMID:21708822; http://dx.doi.org/10.1136/gut.2011.238386
14. Werber D, Hille K, Frank C, Dehnert M, Altmann D, Müller-Nordhorn J, Koch J, Stark K. Years of potential life lost for six major enteric pathogens, Germany, 2004-2008. Epidemiol Infect 2013; 141:961-8; PMID:22813426; http://dx.doi.org/10.1017/S0950268812001550
15. Verhoef L, Koopmans M, VAN Pelt W, Duizer E, Haagsma J, Werber D, VAN Asten L, Havelaar A. The estimated disease burden of norovirus in The Netherlands. Epidemiol Infect 2013; 141:496-506; PMID:22595489; http://dx.doi.org/10.1017/S0950268812000799
16. Lopman BA, Hall AJ, Curns AT, Parashar UD. Increasing rates of gastroenteritis hospital discharges in US adults and the contribution of norovirus, 1996-2007. Clin Infect Dis 2011; 52:466-74; PMID:21258098; http://dx.doi.org/10.1093/cid/ciq163
17. Gastañaduy PA, Hall AJ, Curns AT, Parashar UD, Lopman BA. Burden of norovirus gastroenteritis in the ambulatory setting - United States, 2001-2009. J Infect Dis 2013; 207:1058-65; PMID:23300161; http://dx.doi.org/10.1093/ infdis/jis942
18. Hall AJ, Curns AT, McDonald LC, Parashar UD, Lopman BA. The roles of Clostridium difficile and norovirus among gastroenteritis-associated deaths in the United States, 1999-2007. [Epub ahead of print]. Clin Infect Dis 2012; 55:216-23; PMID:22491338; http://dx.doi.org/10.1093/cid/cis386
19. Payne DC, Vinjé J, Szilagyi PG, Edwards KM, Staat MA, Weinberg GA, Hall CB, Chappell J, Bernstein DI, Curns AT, et al. Norovirus and medically attended gastroenteritis in U.S. children. N Engl J Med 2013; 368:1121-30; PMID:23514289; http://dx.doi.org/10.1056/NEJMsa1206589
20. Bartsch SM, Lopman BA, Hall AJ, Parashar UD, Lee BY. The potential economic value of a human norovirus vaccine for the United States. Vaccine 2012; 30:7097-104; PMID:23026689; http://dx.doi.org/10.1016/j.vaccine.2012.09.040
21. Hoffmann S, Batz MB, Morris JG Jr. Annual cost of illness and quality-adjusted life year losses in the United States due to 14 foodborne pathogens. J Food Prot 2012; 75:1292-302; PMID:22980013; http://dx.doi.org/10. 4315/0362-028X.JFP-11-417
22. Johnston CP, Qiu H, Ticehurst JR, Dickson C, Rosenbaum P, Lawson P, Stokes AB, Lowenstein CJ, Kaminsky M, Cosgrove SE, et al. Outbreak management and implications of a nosocomial norovirus outbreak. Clin Infect Dis 2007; 45:534-40; PMID:17682985; http://dx.doi.org/10.1086/520666
23. Fretz R, Schmid D, Jelovcan S, Tschertou R, Krassnitzer E, Schirmer M, Hell M, Allerberger F. An outbreak of norovirus gastroenteritis in an Austrian hospital, winter 2006-2007. Wien Klin Wochenschr 2009; 121:137-43; PMID:19280140; http://dx.doi.org/10.1007/s00508-008-1135-x
24. Zingg W, Colombo C, Jucker T, Bossart W, Ruef C. Impact of an outbreak of norovirus infection on hospital resources. Infect Control Hosp Epidemiol 2005; 26:263-7; PMID:15796278; http://dx.doi.org/10.1086/502537
25. Danial J, Cepeda JA, Cameron F, Cloy K, Wishart D, Templeton KE. Epidemiology and costs associated with norovirus outbreaks in NHS Lothian, Scotland 2007-2009. J Hosp Infect 2011; 79:354-8; PMID:21955453; http://dx.doi.org/10.1016/j. jhin.2011.06.018
26. Lee BY, Wettstein ZS, McGlone SM, Bailey RR, Umscheid CA, Smith KJ, Muder RR. Economic value of norovirus outbreak control measures in healthcare settings. Clin Microbiol Infect 2011; 17:640-6; PMID:20731684; http://dx.doi. org/10.1111/j.1469-0691.2010.03345.x
27. Lee BY, McGlone SM, Bailey RR, Wettstein ZS, Umscheid CA, Muder RR. Economic impact of outbreaks of norovirus infection in hospitals. Infect Control Hosp Epidemiol 2011; 32:191-3; PMID:21460478; http://dx.doi.org/10.1086/657910
28. Hall AJ, Rosenthal M, Gregoricus N, Greene SA, Ferguson J, Henao OL, Vinjé J, Lopman BA, Parashar UD, Widdowson MA. Incidence of acute gastroenteritis and role of norovirus, Georgia, USA, 2004-2005. Emerg Infect Dis 2011; 17:1381-8; PMID:21801613
29. Zintz C, Bok K, Parada E, Barnes-Eley M, Berke T, Staat MA, Azimi P, Jiang X, Matson DO. Prevalence and genetic characterization of caliciviruses among children hospitalized for acute gastroenteritis in the United States. Infect Genet Evol 2005; 5:281-90; PMID:15737920; http://dx.doi.org/10.1016/j. meegid.2004.06.010
30. Chhabra P, Payne DC, Szilagyi PG, Edwards KM, Staat MA, Shirley SH, Wikswo M, Nix WA, Lu X, Parashar UD, et al. Etiology of viral gastroenteritis in children <5 years of age in the United States, 2008-2009. J Infect Dis 2013; 208:790-800; PMID:23757337; http://dx.doi.org/10.1093/infdis/jit254
31. Podkolzin AT, Fenske EB, Abramycheva NY, Shipulin GA, Sagalova OI, Mazepa VN, Ivanova GN, Semena AV, Tagirova ZG, Alekseeva MN, et al. Hospitalbased surveillance of rotavirus and other viral agents of diarrhea in children and adults in Russia, 2005-2007. J Infect Dis 2009; 200(Suppl 1):S228-33; PMID:19817602; http://dx.doi.org/10.1086/605054
32. Lee BY, McGlone SM. Pricing of new vaccines. Hum Vaccin 2010; 6:619-26; PMID:20861678; http://dx.doi.org/10.4161/hv.6.8.11563
33. Riddle MS, Gutierrez RL, Verdu EF, Porter CK. The chronic gastrointestinal consequences associated with campylobacter. Curr Gastroenterol Rep 2012; 14:395-405; PMID:22864805; http://dx.doi.org/10.1007/s11894-012-0278-0
34. Scallan E, Mahon BE, Hoekstra RM, Griffin PM. Estimates of illnesses, hospitalizations and deaths caused by major bacterial enteric pathogens in young children in the United States. Pediatr Infect Dis J 2013; 32:217-21; PMID:23249909
35. Toljander J, Dovärn A, Andersson Y, Ivarsson S, Lindqvist R. Public health burden due to infections by verocytotoxin-producing Escherichia coli (VTEC) and Campylobacter spp. as estimated by cost of illness and different approaches to model disabilityadjusted life years. Scand J Public Health 2012; 40:294-302; PMID:22312030; http://dx.doi.org/10.1177/1403494811435495
36. Kotloff KL, Nataro JP, Blackwelder WC, Nasrin D, Farag TH, Panchalingam S, Wu Y, Sow SO, Sur D, Breiman RF, et al. Burden and aetiology of diarrhoeal disease in infants and young children in developing countries (the Global Enteric Multicenter Study, GEMS): a prospective, case-control study. Lancet 2013; 382:209-22; PMID:23680352; http://dx.doi.org/10.1016/S0140-6736(13)60844-2
37. Riddle MS, Tribble DR, Cachafiero SP, Putnam SD, Hooper TI. Development of a travelers' diarrhea vaccine for the military: how much is an ounce of prevention really worth? Vaccine 2008; 26:2490-502; PMID:18417259; http://dx.doi.org/10.1016/j.vaccine.2008.03.008
38. Murugaiah C. The burden of cholera. Crit Rev Microbiol 2011; 37:337-48; PMID:21823927; http://dx.doi.org/10.3109/1040841X.2011.603288
39. World Health Organization. Cholera, 2012. Wkly Epidemiol Rec 2013; 88:321-34; PMID:23980290
40. Sarker AR, Islam Z, Khan IA, Saha A, Chowdhury F, Khan AI, Qadri F, Khan JA. Cost of illness for cholera in a high risk urban area in Bangladesh: an analysis from household perspective. BMC Infect Dis 2013; 13:518; PMID:24188717; http://dx.doi.org/10.1186/1471-2334-13-518
41. Kirigia JM, Sambo LG, Yokouide A, Soumbey-Alley E, Muthuri LK, Kirigia DG. Economic burden of cholera in the WHO African region. BMC Int Health Hum Rights 2009; 9:8; PMID:19405948; http://dx.doi.org/10.1186/1472-698X-9-8
42. Poulos C, Riewpaiboon A, Stewart JF, Clemens J, Guh S, Agtini M, Sur D, Islam Z, Lucas M, Whittington D; DOMI Cholera COI Study Group. Costs of illness due to endemic cholera. Epidemiol Infect 2012; 140:500-9; PMID:21554781; http://dx.doi.org/10.1017/S0950268811000513
43. Schaetti C, Weiss MG, Ali SM, Chaignat CL, Khatib AM, Reyburn R, Duintjer Tebbens RJ, Hutubessy R. Costs of illness due to cholera, costs of immunization and cost-effectiveness of an oral cholera mass vaccination campaign in Zanzibar. PLoS Negl Trop Dis 2012; 6:e1844; PMID:23056660; http://dx.doi.org/10. 1371/journal.pntd.0001844
44. Jeuland M, Cook J, Poulos C, Clemens J, Whittington D; DOMI Cholera Economics Study Group. Cost-effectiveness of new-generation oral cholera vaccines: a multisite analysis. Value Health 2009; 12:899-908; PMID:19824189; http://dx.doi.org/10.1111/j.1524-4733.2009.00562.x
45. Maskery B, DeRoeck D, Levin A, Kim YE, Wierzba TF, Clemens JD. Strategy, demand, management, and costs of an international cholera vaccine stockpile. J Infect Dis 2013; 208(Suppl 1):S15-22; PMID:24101640; http://dx.doi.org/10.1093/ infdis/jit233
46. Khan IA, Saha A, Chowdhury F, Khan AI, Uddin MJ, Begum YA, Riaz BK, Islam S, Ali M, Luby SP, et al. Coverage and cost of a large oral cholera vaccination program in a high-risk cholera endemic urban population in Dhaka, Bangladesh. Vaccine 2013; 31:6058-64; PMID:24161413; http://dx.doi.org/10.1016/j.vaccine. 2013.10.021
47. Dubberke ER, Wertheimer AI. Review of current literature on the economic burden of Clostridium difficile infection. Infect Control Hosp Epidemiol 2009; 30:57-66; PMID:19049438; http://dx.doi.org/10.1086/592981
48. Dubberke E. Clostridium difficile infection: the scope of the problem. J Hosp Med 2012; 7(Suppl 3):S1-4; PMID:22407993; http://dx.doi.org/10.1002/jhm. 1916
49. Depestel DD, Aronoff DM. Epidemiology of Clostridium difficile infection. J Pharm Pract 2013; 26:464-75; PMID:24064435; http://dx.doi.org/10.1177/ 0897190013499521
50. Ghantoji SS, Sail K, Lairson DR, DuPont HL, Garey KW. Economic healthcare costs of Clostridium difficile infection: a systematic review. J Hosp Infect 2010; 74:309-18; PMID:20153547; http://dx.doi.org/10.1016/j.jhin.2009.10.016
51. McGlone SM, Bailey RR, Zimmer SM, Popovich MJ, Tian Y, Ufberg P, Muder RR, Lee BY. The economic burden of Clostridium difficile. Clin Microbiol Infect 2012; 18:282-9; PMID:21668576; http://dx.doi.org/10.1111/j.1469-0691.2011.03571. x
52. Dubberke ER, Olsen MA. Burden of Clostridium difficile on the healthcare system. Clin Infect Dis 2012; 55(Suppl 2):S88-92; PMID:22752870; http://dx.doi.org/10.1093/cid/cis335
53. Tabak YP, Zilberberg MD, Johannes RS, Sun X, McDonald LC. Attributable burden of hospital-onset Clostridium difficile infection: a propensity score matching study. Infect Control Hosp Epidemiol 2013; 34:588-96; PMID:23651889; http://dx.doi.org/10.1086/670621
54. Lee BY, Popovich MJ, Tian Y, Bailey RR, Ufberg PJ, Wiringa AE, Muder RR. The potential value of Clostridium difficile vaccine: an economic computer simulation model. Vaccine 2010; 28:5245-53; PMID:20541582; http://dx.doi.org/10. 1016/j.vaccine.2010.05.062
55. Gupta SK, Keck J, Ram PK, Crump JA, Miller MA, Mintz ED. Part III. Analysis of data gaps pertaining to enterotoxigenic Escherichia coli infections in low and medium human development index countries, 1984-2005. Epidemiol Infect 2008; 136:721-38; PMID:17686197; http://dx.doi.org/10.1017/S095026880700934X
56. Lundkvist J, Steffen R, Jönsson B. Cost-benefit of WC/rBS oral cholera vaccine for vaccination against ETEC-caused travelers' diarrhea. J Travel Med 2009; 16:28-34; PMID:19192125; http://dx.doi.org/10.1111/j.1708-8305. 2008.00270.x
57. World Health Organization. Future directions for research on enterotoxigenic Escherichia coli vaccines for developing countries. Wkly Epidemiol Rec 2006; 81:97-104; PMID:16671213
58. Program for Appropriate Technology in Health (PATH), Bio Ventures for Global Health (BVGH). The case for investment in enterotoxigenic Escherichia coli vaccines. Seattle, WA 2011. Available from: http://www.path.org/ publications/files/VAC-etec-investment-rpt.pdf
59. Grimwood K, Lambert SB, Milne RJ. Rotavirus infections and vaccines: burden of illness and potential impact of vaccination. Paediatr Drugs 2010; 12:235-56; PMID:20593908; http://dx.doi.org/10.2165/11537200-000000000-00000
60. Parashar UD, Burton A, Lanata C, Boschi-Pinto C, Shibuya K, Steele D, Birmingham M, Glass RI. Global mortality associated with rotavirus disease among children in 2004. J Infect Dis 2009; 200(Suppl 1):S9-15; PMID:19817620; http://dx.doi.org/10.1086/605025
61. Milne RJ, Grimwood K. Budget impact and cost-effectiveness of including a pentavalent rotavirus vaccine in the New Zealand childhood immunization schedule. Value Health 2009; 12:888-98; PMID:19490550; http://dx.doi.org/10. 1111/j.1524-4733.2009.00534.x
62. Chen K-T, Fan S-F, Tang R-B, Huang YF, Lee PI, Chen PY, Tang CW, Chen HC. Hospital-based study of the economic burden associated with rotavirus diarrhea in Taiwan. Vaccine 2007; 25:4266-72; PMID:17360079; http://dx.doi.org/10.1016/j. vaccine.2007.02.056
63. Chang WC, Yen C, Chi CL, Wu FT, Huang YC, Lin JS, Huang FC, Tate JE, Wu HS, Hsiung CA. Cost-effectiveness of rotavirus vaccination programs in Taiwan. Vaccine 2013; 31:5458-65; PMID:24060569; http://dx.doi.org/10.1016/j.vaccine. 2013.08.103
64. Tate JE, Rheingans RD, O'Reilly CE, Obonyo B, Burton DC, Tornheim JA, Adazu K, Jaron P, Ochieng B, Kerin T, et al. Rotavirus disease burden and impact and cost-effectiveness of a rotavirus vaccination program in kenya. J Infect Dis 2009; 200(Suppl 1):S76-84; PMID:19817618; http://dx.doi.org/10.1086/605058
65. Fischer TK, Anh DD, Antil L, Cat ND, Kilgore PE, Thiem VD, Rheingans R, Tho H, Glass RI, Bresee JS. Health care costs of diarrheal disease and estimates of the cost-effectiveness of rotavirus vaccination in Vietnam. J Infect Dis 2005; 192:1720-6; PMID:16235169; http://dx.doi.org/10.1086/497339
66. Flem ET, Latipov R, Nurmatov ZS, Xue Y, Kasymbekova KT, Rheingans RD. Costs of diarrheal disease and the cost-effectiveness of a rotavirus vaccination program in kyrgyzstan. J Infect Dis 2009; 200(Suppl 1):S195-202; PMID:19817600; http://dx.doi.org/10.1086/605040
67. Smith ER, Rowlinson EE, Iniguez V, Etienne KA, Rivera R, Mamani N, Rheingans R, Patzi M, Halkyer P, Leon JS. Cost-effectiveness of rotavirus vaccination in Bolivia from the state perspective. Vaccine 2011; 29:6704-11; PMID:21624421; http://dx.doi.org/10.1016/j.vaccine.2011.05.038
68. Takemoto MLS, Bahia L, Toscano CM, Araujo DV. Systematic review of studies on rotavirus disease cost-of-illness and productivity loss in Latin America and the Caribbean. Vaccine 2013; 31(Suppl 3):C45-57; PMID:23777691; http://dx.doi.org/10.1016/j.vaccine.2013.05.031
69. Widdowson MA, Meltzer MI, Zhang X, Bresee JS, Parashar UD, Glass RI. Cost-effectiveness and potential impact of rotavirus vaccination in the United States. Pediatrics 2007; 119:684-97; PMID:17403839; http://dx.doi.org/10.1542/ peds.2006-2876
70. Cortes JE, Curns AT, Tate JE, Cortese MM, Patel MM, Zhou F, Parashar UD. Rotavirus vaccine and health care utilization for diarrhea in U.S. children. N Engl J Med 2011; 365:1108-17; PMID:21992123; http://dx.doi.org/10.1056/ NEJMoa1000446
71. Coyle D, Coyle K, Bettinger JA, Halperin SA, Vaudry W, Scheifele DW, Le Saux N. Cost effectiveness of infant vaccination for rotavirus in Canada. Can J Infect Dis Med Microbiol 2012; 23:71-7; PMID:23730312
72. Fisman DN, Chan CH, Lowcock E, Naus M, Lee V. Effectiveness and cost-effectiveness of pediatric rotavirus vaccination in British Columbia: a model-based evaluation. Vaccine 2012; 30:7601-7; PMID:23107595; http://dx.doi.org/10.1016/j.vaccine.2012.10.034
73. Atkins KE, Shim E, Carroll S, Quilici S, Galvani AP. The cost-effectiveness of pentavalent rotavirus vaccination in England and Wales. Vaccine 2012; 30:6766-76; PMID:23000223; http://dx.doi.org/10.1016/j.vaccine. 2012.09.025
74. Tu HAT, Rozenbaum MH, de Boer PT, Noort AC, Postma MJ. An update of "Cost-effectiveness of rotavirus vaccination in the Netherlands: the results of a Consensus Rotavirus Vaccine model". BMC Infect Dis 2013; 13:54; PMID:23363553; http://dx.doi.org/10.1186/1471-2334-13-54
75. Bruijning-Verhagen P, Mangen M-JJ, Felderhof M, Hartwig NG, van Houten M, Winkel L, de Waal WJ, Bonten MJ. Targeted rotavirus vaccination of high-risk infants; a low cost and highly cost-effective alternative to universal vaccination. BMC Med 2013; 11:112; PMID:23622110; http://dx.doi.org/10.1186/ 1741-7015-11-112
76. Diez-Domingo J, Suriñach NL, Alcalde NM, Betegón L, Largeron N, Trichard M. Burden of paediatric Rotavirus Gastroenteritis (RVGE) and potential benefits of a universal Rotavirus vaccination programme with a pentavalent vaccine in Spain. BMC Public Health 2010; 10:469; PMID:20698958; http://dx.doi.org/10.1186/1471-2458-10-469
77. van Hoek AJ, Ngama M, Ismail A, Chuma J, Cheburet S, Mutonga D, Kamau T, Nokes DJ. A cost effectiveness and capacity analysis for the introduction of universal rotavirus vaccination in Kenya: comparison between Rotarix and RotaTeq vaccines. PLoS One 2012; 7:e47511; PMID:23115650; http://dx.doi.org/10.1371/ journal.pone.0047511
78. Liu N, Yen C, Fang ZY, Tate JE, Jiang B, Parashar UD, Zeng G, Duan ZJ. Projected health impact and cost-effectiveness of rotavirus vaccination among children <5 years of age in China. Vaccine 2012; 30:6940-5; PMID:22705174; http://dx.doi.org/10.1016/j.vaccine.2012.05.084
79. Suwantika AA, Tu HAT, Postma MJ. Cost-effectiveness of rotavirus immunization in Indonesia: taking breastfeeding patterns into account. Vaccine 2013; 31:3300-7; PMID:23707163; http://dx.doi.org/10.1016/j.vaccine.2013.04.055
80. Atherly DE, Lewis KDC, Tate J, Parashar UD, Rheingans RD. Projected health and economic impact of rotavirus vaccination in GAVI-eligible countries: 2011-2030. Vaccine 2012; 30(Suppl 1):A7-14; PMID:22520139; http://dx.doi.org/10. 1016/j.vaccine.2011.12.096
81. Tu HA, Woerdenbag HJ, Kane S, Rozenbaum MH, Li SC, Postma MJ. Economic evaluations of rotavirus immunization for developing countries: a review of the literature. Expert Rev Vaccines 2011; 10:1037-51; PMID:21806398; http://dx.doi.org/10.1586/erv.11.65
82. Verguet S, Murphy S, Anderson B, Johansson KA, Glass R, Rheingans R. Public finance of rotavirus vaccination in India and Ethiopia: an extended cost-effectiveness analysis. Vaccine 2013; 31:4902-10; PMID:23871824; http://dx.doi.org/10.1016/j.vaccine.2013.07.014
83. Kotsopoulos N, Connolly MP, Postma MJ, Hutubessy RC. Fiscal consequences of changes in morbidity and mortality attributed to rotavirus immunisation. Vaccine 2013; 31:5430-4; PMID:24055088; http://dx.doi.org/10.1016/j.vaccine. 2013.09.002
84. von Seidlein L, Kim DR, Ali M, Lee H, Wang X, Thiem VD, Canh G, Chaicumpa W, Agtini MD, Hossain A, et al. A multicentre study of Shigella diarrhoea in six Asian countries: disease burden, clinical manifestations, and microbiology. PLoS Med 2006; 3:e353; PMID:16968124; http://dx.doi.org/10.1371/journal.pmed. 0030353
85. Riewpaiboon A, Youngkong S, Sreshthaputra N, Stewart JF, Samosornsuk S, Chaicumpa W, von Seidlein L, Clemens JD. A cost function analysis of shigellosis in Thailand. Value Health 2008; 11(Suppl 1):S75-83; PMID:18387071; http://dx.doi.org/10.1111/j.1524-4733.2008.00370.x
86. Ziv T, Heymann AD, Azuri J, Leshno M, Cohen D. Assessment of the underestimation of childhood diarrhoeal disease burden in Israel. Epidemiol Infect 2011; 139:1379-87; PMID:21087537; http://dx.doi.org/10.1017/ S0950268810002554
87. Gargouri N, Walke H, Belbeisi A, Hadadin A, Salah S, Ellis A, Braam HP, Angulo FJ. Estimated burden of human Salmonella, Shigella, and Brucella infections in Jordan, 2003-2004. Foodborne Pathog Dis 2009; 6:481-6; PMID:19415972; http://dx.doi.org/10.1089/fpd.2008.0192
88. Rolfo F, Marin GH, Silberman M, Pattin J, Giugnio S, Gatti B, Bettiol M, Rigoni A. Epidemiological study of shigellosis in an urban area of Argentina. J Infect Dev Ctries 2012; 6:324-8; PMID:22505441
89. Arvelo W, Blum LS, Nahar N, von Seidlein L, Nahar L, Pack RP, Brooks AW, Pach A, Breiman RF, Luby SP, et al. Community perceptions of bloody diarrhoea in an urban slum in South Asia: implications for introduction of a Shigella vaccine. Epidemiol Infect 2011; 139:599-605; PMID:20546637; http://dx.doi.org/ 10.1017/S0950268810001391
90. Fletcher SM, Stark D, Harkness J, Ellis J. Enteric protozoa in the developed world: a public health perspective. Clin Microbiol Rev 2012; 25:420-49; PMID:22763633; http://dx.doi.org/10.1128/CMR.05038-11
91. Nelson EAS, de Quadros CA, Santosham M, Parashar UD, Steele D. Overcoming perceptions of financial barriers to rotavirus vaccine introduction in Asia. Hum Vaccin Immunother 2013; 9:1-9; PMID:23955246; http://dx.doi.org/10.4161/hv. 26107
92. DeRoeck D, Clemens JD, Nyamete A, Mahoney RT. Policymakers' views regarding the introduction of new-generation vaccines against typhoid fever, shigellosis and cholera in Asia. Vaccine 2005; 23:2762-74; PMID:15780724; http://dx.doi.org/10.1016/j.vaccine.2004.11.044
93. Lee BY, Assi TM, Rajgopal J, Norman BA, Chen SI, Brown ST, Slayton RB, Kone S, Kenea H, Welling JS, et al. Impact of introducing the pneumococcal and rotavirus vaccines into the routine immunization program in Niger. Am J Public Health 2012; 102:269-76; PMID:21940923; http://dx.doi.org/10.2105/AJPH.2011. 300218
94. Lee BY, Assi T-M, Rookkapan K, Wateska AR, Rajgopal J, Sornsrivichai V, Chen SI, Brown ST, Welling J, Norman BA, et al. Maintaining vaccine delivery following the introduction of the rotavirus and pneumococcal vaccines in Thailand. PLoS One 2011; 6:e24673; PMID:21931805; http://dx.doi.org/10.1371/ journal.pone.0024673
95. Haidari LA, Connor DL, Wateska AR, Brown ST, Mueller LE, Norman BA, Schmitz MM, Paul P, Rajgopal J, Welling JS, et al. Augmenting transport versus increasing cold storage to improve vaccine supply chains. PLoS One 2013; 8:e64303; PMID:23717590; http://dx.doi.org/10.1371/journal.pone.0064303